Literature DB >> 18440328

The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study.

Braxton D Mitchell1, Patrick F McArdle, Haiqing Shen, Evadnie Rampersaud, Toni I Pollin, Lawrence F Bielak, Cashell Jaquish, Julie A Douglas, Marie-Hélène Roy-Gagnon, Paul Sack, Rosalie Naglieri, Scott Hines, Richard B Horenstein, Yen-Pei C Chang, Wendy Post, Kathleen A Ryan, Nga Hong Brereton, Ruth E Pakyz, John Sorkin, Coleen M Damcott, Jeffrey R O'Connell, Charles Mangano, Mary Corretti, Robert Vogel, William Herzog, Matthew R Weir, Patricia A Peyser, Alan R Shuldiner.   

Abstract

BACKGROUND: The etiology of cardiovascular disease (CVD) is multifactorial. Efforts to identify genes influencing CVD risk have met with limited success to date, likely because of the small effect sizes of common CVD risk alleles and the presence of gene by gene and gene by environment interactions.
METHODS: The HAPI Heart Study was initiated in 2002 to measure the cardiovascular response to 4 short-term interventions affecting cardiovascular risk factors and to identify the genetic and environmental determinants of these responses. The measurements included blood pressure responses to the cold pressor stress test and to a high salt diet, triglyceride excursion in response to a high-fat challenge, and response in platelet aggregation to aspirin therapy.
RESULTS: The interventions were carried out in 868 relatively healthy Amish adults from large families. The heritabilities of selected response traits for each intervention ranged from 8% to 38%, suggesting that some of the variation associated with response to each intervention can be attributed to the additive effects of genes.
CONCLUSIONS: Identifying these response genes may identify new mechanisms influencing CVD and may lead to individualized preventive strategies and improved early detection of high-risk individuals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18440328      PMCID: PMC2443415          DOI: 10.1016/j.ahj.2008.01.019

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  13 in total

1.  QTL influencing blood pressure maps to the region of PPH1 on chromosome 2q31-34 in Old Order Amish.

Authors:  W C Hsueh; B D Mitchell; J L Schneider; M J Wagner; C J Bell; E Nanthakumar; A R Shuldiner
Journal:  Circulation       Date:  2000-06-20       Impact factor: 29.690

2.  Quantitative-trait homozygosity and association mapping and empirical genomewide significance in large, complex pedigrees: fasting serum-insulin level in the Hutterites.

Authors:  Mark Abney; Carole Ober; Mary Sara McPeek
Journal:  Am J Hum Genet       Date:  2002-03-04       Impact factor: 11.025

3.  Towards a complete North American Anabaptist Genealogy II: analysis of inbreeding.

Authors:  R Agarwala; A A Schäffer; J F Tomlin
Journal:  Hum Biol       Date:  2001-08       Impact factor: 0.553

4.  Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins.

Authors:  S Zdravkovic; A Wienke; N L Pedersen; M E Marenberg; A I Yashin; U De Faire
Journal:  J Intern Med       Date:  2002-09       Impact factor: 8.989

5.  Accounting for relatedness in family based genetic association studies.

Authors:  P F McArdle; J R O'Connell; T I Pollin; M Baumgarten; A R Shuldiner; P A Peyser; B D Mitchell
Journal:  Hum Hered       Date:  2007-06-14       Impact factor: 0.444

6.  Population studies and the Old Order Amish.

Authors:  H E Cross
Journal:  Nature       Date:  1976-07-01       Impact factor: 49.962

7.  Family history is a coronary heart disease risk factor in the Second Northwick Park Heart Study.

Authors:  E Hawe; P J Talmud; G J Miller; S E Humphries
Journal:  Ann Hum Genet       Date:  2003-03       Impact factor: 1.670

8.  Are common disease susceptibility alleles the same in outbred and founder populations?

Authors:  Dina L Newman; Sabine Hoffjan; Catherine Bourgain; Mark Abney; Raluca I Nicolae; Elle T Profits; Michael A Grow; Karen Walker; Lori Steiner; Rodney Parry; Rebecca Reynolds; Mary Sara McPeek; Suzanne Cheng; Carole Ober
Journal:  Eur J Hum Genet       Date:  2004-07       Impact factor: 4.246

9.  Genetic susceptibility to death from coronary heart disease in a study of twins.

Authors:  M E Marenberg; N Risch; L F Berkman; B Floderus; U de Faire
Journal:  N Engl J Med       Date:  1994-04-14       Impact factor: 91.245

10.  Major risk factors as antecedents of fatal and nonfatal coronary heart disease events.

Authors:  Philip Greenland; Maria Deloria Knoll; Jeremiah Stamler; James D Neaton; Alan R Dyer; Daniel B Garside; Peter W Wilson
Journal:  JAMA       Date:  2003-08-20       Impact factor: 56.272

View more
  78 in total

1.  Mapping genes that predict treatment outcome in admixed populations.

Authors:  T M Baye; R A Wilke
Journal:  Pharmacogenomics J       Date:  2010-10-05       Impact factor: 3.550

2.  Heritability of serum sodium concentration: evidence for sex- and ethnic-specific effects.

Authors:  Beth Wilmot; V Saroja Voruganti; Yen-Pei C Chang; Yi Fu; Zhan Chen; Herman A Taylor; James G Wilson; Teresa Gipson; Vallabh O Shah; Jason G Umans; Michael F Flessner; Robert Hitzemann; Alan R Shuldiner; Anthony G Comuzzie; Shannon McWeeney; Philip G Zager; Jean W Maccluer; Shelley A Cole; David M Cohen
Journal:  Physiol Genomics       Date:  2011-12-20       Impact factor: 3.107

3.  Improper adjustment for baseline in genetic association studies of change in phenotype.

Authors:  P F McArdle; B W Whitcomb
Journal:  Hum Hered       Date:  2008-12-15       Impact factor: 0.444

4.  Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study).

Authors:  Haiqing Shen; William Herzog; MaryAnn Drolet; Ruth Pakyz; Sylvia Newcomer; Paul Sack; Heidi Karon; Kathleen A Ryan; Yiju Zhao; Xiaolian Shi; Braxton D Mitchell; Alan R Shuldiner
Journal:  Am J Cardiol       Date:  2009-06-21       Impact factor: 2.778

5.  Familial aggregation of tobacco use behaviors among Amish men.

Authors:  Katie L Nugent; Amber Million-Mrkva; Joshua Backman; Sarah H Stephens; Robert M Reed; Peter Kochunov; Toni I Pollin; Alan R Shuldiner; Braxton D Mitchell; L Elliot Hong
Journal:  Nicotine Tob Res       Date:  2014-02-28       Impact factor: 4.244

6.  A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.

Authors:  Toni I Pollin; Coleen M Damcott; Haiqing Shen; Sandra H Ott; John Shelton; Richard B Horenstein; Wendy Post; John C McLenithan; Lawrence F Bielak; Patricia A Peyser; Braxton D Mitchell; Michael Miller; Jeffrey R O'Connell; Alan R Shuldiner
Journal:  Science       Date:  2008-12-12       Impact factor: 47.728

7.  The ABCG8 G574R variant, serum plant sterol levels, and cardiovascular disease risk in the Old Order Amish.

Authors:  Richard B Horenstein; Braxton D Mitchell; Wendy S Post; Dieter Lütjohann; Klaus von Bergmann; Kathleen A Ryan; Michael Terrin; Alan R Shuldiner; Nanette I Steinle
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12-13       Impact factor: 8.311

8.  PedHunter 2.0 and its usage to characterize the founder structure of the Old Order Amish of Lancaster County.

Authors:  Woei-Jyh Lee; Toni I Pollin; Jeffrey R O'Connell; Richa Agarwala; Alejandro A Schäffer
Journal:  BMC Med Genet       Date:  2010-05-02       Impact factor: 2.103

9.  Circulating CD34+ Cell Count is Associated with Extent of Subclinical Atherosclerosis in Asymptomatic Amish Men, Independent of 10-Year Framingham Risk.

Authors:  Lawrence F Bielak; Richard B Horenstein; Kathleen A Ryan; Patrick F Sheedy; John A Rumberger; Keith Tanner; Wendy Post; Braxton D Mitchell; Alan R Shuldiner; Patricia A Peyser
Journal:  Clin Med Cardiol       Date:  2009-05-27

10.  Extent and distribution of linkage disequilibrium in the Old Order Amish.

Authors:  Cristopher V Van Hout; Albert M Levin; Evadnie Rampersaud; Haiqing Shen; Jeffrey R O'Connell; Braxton D Mitchell; Alan R Shuldiner; Julie A Douglas
Journal:  Genet Epidemiol       Date:  2010-02       Impact factor: 2.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.